GDC-0349

DB13072InvestigationalSmall molecule

GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₄H₃₂N₆O₃ · 452.559 g/mol (avg)
Code names: GDC-0349

Resolves to

Compound

Structure

InChIKeyRGJOJUGRHPQXGF-INIZCTEOSA-NSMILESCCNC(=O)NC1=CC=C(C=C1)C1=NC2=C(CCN(C2)C2COC2)C(=N1)N1CCOC[C@@H]1C

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with GDC-0349, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.